Quarterlies Top 5: Here’s another online market place that’s rising today
There was another online market place on the ASX that gained after releasing its quarterly today – HiPages (ASX:HPG).
ASX companies have to lodge quarterly reports by the last trading day of January, April, July and October.
This ASX-listed company is an online market place like Airtasker but it has a focus on home improvement jobs and operates as a subscription service for tradies.
It reported 18 per cent growth in quarterly recurring revenues and FY21 to date revenue, both growing by 18 per cent to $14.3 million and $41.2 million. 95 per cent of its revenue is recurring.
CEO Roby Sharon-Zipser said it was another quarter of strong growth noting that jobs grew by 17 per cent as the COVID-19 trend of higher investments in home improvement projects continued.
“Our subscription model is delivering higher average revenue per tradie and better retention rates as tradies switch from our legacy transaction offering at a faster rate than expected,” he said.
HiPages’ shares are still slightly below its IPO price but rose by over 6 per cent this morning.
Amplia was the biggest gainer as at 11am (AEST) although it also released pre-clinical data which showed that its anti-cancer and fibrosis drug might be able to help treat pancreatic cancer.
It completed dosing in a Phase 1 clinical trial earlier in the quarter. It is consequently planning a Phase 2 clinical trial of its AMP945 drug in pancreatic cancer patients.
CEO John Lambert declared the March quarter had seen solid foundations laid for the next stage of the company’s growth.
You might know this company as a condom-maker but it parted ways with that business back in 2017.
Ansell specialises in another type of protective equipment, something that has been in hot demand due to COVID-19 and it is reaping the benefits.
The company upped its guidance, expecting year on year sales growth for this half of the financial year to be higher than the 24.5 per cent made in the previous half.
It also expects higher earnings per share.
For the WA gas stock, today was just a recap of the quarter that had been but it was a busy one for the company.
CEO Stuart Nicholls declared the foundations were in place for its ambitions with solid drilling results, winning new acreage and a $75 million capital raise.
The cancer therapy stock has a drug, PAT-DX1, that aims to stop cancer sells self-repairing DNA when it breaks down – one of the key ways cancer cells stay alive.
It is aiming to get its drug into clinical development in the first half of 2022 and it made substantial steps this quarter.
Patrys was granted further patents and established a high-yield cell line for commercial production. As well as this it completed further preclinical studies that showed it could reduce tumour growth in animal models of non-TNBC (triple negative breast cancer) and colon cancer.
After lagging for much of its first 12 months as a listed company the medicinal cannabis data and drug maker company has been growing along with the rest of the cannabis sector in several weeks thanks to the breaking down of numerous regulatory barriers around the world.
But it also notched up several feats during the quarter including opening new medical clinics and continuing development on its drug programs.
It is hoping to eventually register an over-the-counter CBD product with the TGA and its most promising candidate EMD-003. It teamed up with fellow cannabis listee Cann Group (ASX:CAN) to do this only last month.